Carboplatin-based chemotherapy and surgery: A cost effective treatment strategy for malignant extracranial germ cell tumours in the developing world

Authors

  • Marc Hendricks MD, FC Paeds, CMO,

    Corresponding author
    1. Paediatric Haematology Oncology Service, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa
    • Haematology Oncology Service, Red Cross War Memorial Children's Hospital, Klipfontein Road, Rondebosch, Cape Town 7700, South Africa.
    Search for more papers by this author
    • Senior Specialist, Paediatric Oncologist.

  • Alan Davidson MD, FC Paeds, CMO, MPhil,

    1. Paediatric Haematology Oncology Service, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa
    Search for more papers by this author
    • Senior Specialist and Head, Paediatric Oncologist.

  • Komala Pillay MD, FCPath, FRCPath, MMed Anat Path,

    1. Anatomical Pathology Service, National Health Laboratory Services, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa
    Search for more papers by this author
    • Histopathologist and Senior Lecturer.

  • Farieda Desai MD, FC Paeds,

    1. Paediatric Haematology Oncology Service, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa
    Search for more papers by this author
    • Senior Specialist, Paediatric Oncologist.

  • Alastair Millar MDFRCS, FRACS (Paed. Surg.), FCS, DCH

    1. Department of Paediatric Surgery, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa
    Search for more papers by this author
    • Chief Specialist and Head.


  • Conflict of interest: Nothing to report.

Abstract

Nineteen children with malignant extracranial germ cell tumours (MEGCT), were treated at our institution with a combination of carboplatin-based chemotherapy and surgery from 1992 to 2008. Seventeen are long term survivors. Chemotherapy was administered on an outpatient basis and required no monitoring of GFR or auditory function. There were no deaths from toxicity or infection. Blood product use was low. Carboplatin-based therapy achieved excellent results in our patient population and constitutes more than a US $1,800 saving per patient compared to regimens containing cisplatin. This has application in resource limited settings. Pediatr Blood Cancer 2011;57:172–174. © 2011 Wiley-Liss, Inc.

Ancillary